First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC) therapy, TLX591 (177Lu-rosopatamab tetraxetan). TLX591 is a rADC composed of a high-specificity PSMA-targeting antibody, chelator linker, and cytotoxic lutetium (177Lu) payload. The PSMA-targeted monoclonal antibody (mAb) ap

Related Keywords

United States ,Switzerland ,United Kingdom ,Japan ,Australia ,Melbourne ,Victoria ,Canada ,Belgium ,Australian ,Nat Lenzo ,Colin Hayward ,Telix Pharmaceuticals ,Telix Pharmaceuticals Limited Disclosure Committee ,Australian Securities Exchange ,Drug Administration ,Genesiscare Group Clinical ,Genesiscare Contract Research Organisation ,Health Canada ,Australian Therapeutic Goods Administration ,God Hospital Murdoch ,Genesiscare Group Clinical Director Theranostics ,Principal Investigator ,Group Chief Medical Officer ,Professor Lenzo ,Telix Pharmaceuticals Limited ,Contract Research Organisation ,Global Study ,Prostate Cancer ,Lobal ,Visma ,Phase Iii Study ,Administered ,Phase Iii ,Safety Profile ,Monoclonal Antibody ,Felix ,